STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.

DNA sequencing with chain-terminating inhibitors

Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,515

Detection of specific sequences among DNA fragments separated by gel electrophoresis

Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,245

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity

Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,512

“Western Blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A

Burnette, W. N. (1981) · Analytical Biochemistry · doi:10.1016/0003-2697(81)90281-5 · Cited by 8,432

Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter

Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., & Green, M. R. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.18.7035 · Cited by 6,324

The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains

Hanks, S. K., Quinn, A. M., & Hunter, T. R. (1988) · Science · doi:10.1126/science.3291115 · Cited by 5,040

Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes

Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741

Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer.

Frohman, M. A., Dush, M. K., & Martin, G. R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.23.8998 · Cited by 4,545

Purification and Characterization of Mouse Hematopoietic Stem Cells

Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2898810 · Cited by 2,908

FLT3-targeted treatment for acute myeloid leukemia

Arai, Y., Chi, S., Minami, Y., & Yanada, M. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03374-0 · Cited by 30

Fms-like Tyrosine Kinase 3 Ligand Stimulation Induces MLL -Rearranged Leukemia Cells into Quiescence Resistant to Antileukemic Agents

Furuichi, Y., Goi, K., Inukai, T., Sato, H., Nemoto, A., Takahashi, K., Akahane, K., Hirose, K., Honna, H., Kuroda, I., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0105 · Cited by 29

RNA Interference Screen in Primary Human T Cells Reveals FLT3 as a Modulator of IL-10 Levels

Astier, A., Bériou, G., Eisenhaure, T., Anderton, S. M., Hafler, D. A., & Hacohen, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902443 · Cited by 28

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

Pratz, K. W., & Luger, S. M. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000022 · Cited by 28

Fiz1, a Novel Zinc Finger Protein Interacting with the Receptor Tyrosine Kinase Flt3

Wolf, I., & Rohrschneider, L. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.21478 · Cited by 28

Mutated Tyrosine Kinases As Therapeutic Targets In Myeloid Leukemias

Sattler, M., Scheijen, B., Weisberg, E., & Griffin, J. D. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_11 · Cited by 28

Reconstitution of human haematopoiesis in non‐obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34+CD38– cells expressing Flk2/Flt3

Ebihara, Y., Wada, M., Ueda, T., Xu, M., Manabe, A., Tanaka, R., Ito, M., Mugishima, H., Asano, S., Nakahata, T., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03820.x · Cited by 28

Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients

Bartram, I., Gökbuget, N., Schlee, C., Heesch, S., Fransecky, L. R., Schwartz, S., Stuhlmann, R., Schäfer-Eckhart, K., Starck, M., Reichle, A., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0051-y · Cited by 27

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Gagelmann, N., Wolschke, C., Klyuchnikov, E., Christopeit, M., Ayuk, F. A., & Kröger, N. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.630429 · Cited by 27

Both Interleukin-3 and Interleukin-6 Are Necessary for Better Ex Vivo Expansion of CD133+ Cells From Umbilical Cord Blood

Bordeaux‐Rego, P., Luzo, Â. C. M., Costa, F. F., Saad, S. T. O., & Crosara-Alberto, D. P. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0098 · Cited by 27

The Molecular Pathogenesis of Gastrointestinal Stromal Tumors

Tarn, C., & Godwin, A. K. (2006) · Clinical Colorectal Cancer · doi:10.3816/ccc.2006.s.002 · Cited by 27

Antitumor therapeutic effects of Salmonella typhimurium containing Flt3 Ligand expression plasmids in melanoma-bearing mouse

Yoon, W., Choi, W. C., Sin, J., & Park, Y. (2007) · Biotechnology Letters · doi:10.1007/s10529-006-9270-9 · Cited by 27

Effects of Flt-3 Ligand in Combination with TPO on the Expansion of Megakaryocytic Progenitors

Li, K., Yang, M., Lam, A. C., Yau, F. W., & Yuen, P. M. P. (2000) · Cell Transplantation · doi:10.1177/096368970000900115 · Cited by 27

CD135 (Flk2/Flt3) Expression by Human Thymocytes Delineates a Possible Role of FLT3‐Ligand in T‐Cell Precursor Proliferation and Differentiation

Bertho, Chapel, A., Loilleux, Frick, Aigueperse, Gorin, & Gourmelon (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00746.x · Cited by 27

Ex vivo expansion of hematopoietic cells and their clinical use.

Aglietta, M., Bertolini, F., Carlo‐Stella, C., Vincentiis, A. D., Lanata, L., Lemoli, R. M., Olivieri, A., Siena, S., Zanon, P., & Tura, S. (1998) · PubMed · Cited by 26

Stem cells and stem cell transplantation.

Carlo‐Stella, C., & Tabilio, A. (1996) · PubMed · Cited by 26

Frequency and Prognostic Relevance ofFLT3Mutations in Saudi Acute Myeloid Leukemia Patients

Elyamany, G., Awad, M., Fadalla, K., Albalawi, M., Shahrani, M. A., & Alabdulaaly, A. (2014) · Advances in Hematology · doi:10.1155/2014/141360 · Cited by 25

Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD

Yang, L., Kitaura, J., Oki, T., Komeno, Y., Ozaki, K., Kiyono, M., Kumagai, H., Nakajima, H., Nosaka, T., Aburatani, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404883 · Cited by 25

MODULATION OF HAEMATOPOIETIC PROGENITOR DEVELOPMENT BY FLT-3 LIGAND

Banu, N., Deng, B., Lyman, S. D., & Avraham, H. K. (1999) · Cytokine · doi:10.1006/cyto.1998.0477 · Cited by 25

Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity

Liu, Y., Huang, H., Chen, Z., Zong, L., & Xiang, J. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.387 · Cited by 25

Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2

Qi, B., Xu, X., Yang, Y., Zhou, Y., Chen, T., Gong, G., Yue, X., Xu, X., Hu, L., & He, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.03.049 · Cited by 24

A novel role for proliferin‐2 in the ex vivo expansion of hematopoietic stem cells

Choong, M. L., Tan, A. C. L., Luo, B., & Lodish, H. F. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00844-5 · Cited by 24

FLT3 inhibitors for the treatment of autoimmune disease

Whartenby, K. A., Small, D., & Calabresi, P. A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1685 · Cited by 24

In vitro propagated dendritic cells from patients with human-papilloma virus-associated preneoplastic lesions of the uterine cervix: use of Flt3 ligand

Hubert, P., Greimers, R., Franzen‐Detrooz, E., Doyen, J., Delanaye, P., Boniver, J., & Delvenne, P. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050507 · Cited by 24

Retroviral-Mediated Gene Transduction of c-kit Into Single Hematopoietic Progenitor Cells From Cord Blood Enhances Erythroid Colony Formation and Decreases Sensitivity to Inhibition by Tumor Necrosis Factor- and Transforming Growth Factor-β1

Lu, L., Heinrich, M. C., Wang, L., Dai, M., Zigler, A. J., Chai, L., & Broxmeyer, H. E. (1999) · Blood · doi:10.1182/blood.v94.7.2319.419k14_2319_2332 · Cited by 23

Expression of Flt3 and c-kit during growth and maturation of human CD34+CD38− cells

Xiao, M., Oppenlander, B. K., Plunkett, J. M., & Dooley, D. C. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00020-x · Cited by 23

Regulatory Roles of the Ligand for Flk2/Flt3 Tyrosine Kinase Receptor on Human Hematopoiesis

Namikawa, R., Muench, M. O., & Roncarolo, M. (1996) · Stem Cells · doi:10.1002/stem.140388 · Cited by 23

Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: Possible application for cancer immunotherapy

Harada, S., Kimura, T., Fujiki, H., Nakagawa, H., Ueda, Y., Itoh, T., Yamagishi, H., & Sonoda, Y. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.6.1461 · Cited by 22

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

Ma, H., Nguyen, B., Li, L., Greenblatt, S. M., Williams, A. B., Zhao, M., Levis, M. J., Rudek, M. A., Duffield, A. S., & Small, D. (2014) · Blood · doi:10.1182/blood-2013-08-523035 · Cited by 22

Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer

Scagliotti, G. V. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm412 · Cited by 22

RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia

Hattori, A., McSkimming, D. I., Kannan, N., & Ito, T. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.015 · Cited by 22

The RARγ Oncogene: An Achilles Heel for Some Cancers

Brown, G., & Petrie, K. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073632 · Cited by 23

Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias

Inomata, M., Takahashi, S., Harigae, H., Kameoka, J., Kaku, M., & Sasaki, T. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.07.015 · Cited by 22

Analysis of FLT3-ITD and FLT3-Asp835 Mutations in de novo Acute Myeloid Leukemia: Evaluation of Incidence, Distribution Pattern, Correlation with Cytogenetics and Characterization of Internal Tandem Duplication from Indian Population

Ahmad, F., Mandava, S., & Das, B. R. (2009) · Cancer Investigation · doi:10.1080/07357900903095649 · Cited by 22

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

Tickenbrock, L., Müller‐Tidow, C., Berdel, W. E., & Serve, H. L. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.153 · Cited by 22

Emerging treatments in acute myeloid leukaemia

Kell, J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.55 · Cited by 22

FLT3/FLK‐2 (STK‐1) Ligand Does Not Stimulate Human Megakaryopoiesis In Vitro

Ratajczak, M. Z., Ratajczak, J., Ford, J. C., Kregenow, R., Marlicz, W. M., & Gewirtz, A. M. (1996) · Stem Cells · doi:10.1002/stem.140146 · Cited by 22

The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia

Shapoorian, H., Zalpoor, H., & Ganjalıkhani-Hakemi, M. (2021) · Blood Science · doi:10.1097/bs9.0000000000000092 · Cited by 21

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives

Orgueira, A. M., Pérez, L. B., Torre, A. M., Raíndo, A. P., López, M. C., Arias, J. Á. D., Ferro, R. F., Rodríguez, B. A., González, M. S., Ferreiro, M. A., et al. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.06989-x · Cited by 21

HIGH EXPRESSION BUT NO INTERNAL TANDEM DUPLICATION OF FLT3 IN NORMAL HEMATOPOIETIC CELLS

Ishii, E., Zaitsu, M., Ihara, K., Hara, T., & Miyazaki, S. (1999) · Pediatric Hematology and Oncology · doi:10.1080/088800199276994 · Cited by 21

Lestaurtinib: a multi-targeted FLT3 inhibitor

Fathi, A. T., & Levis, M. J. (2009) · Expert Review of Hematology · doi:10.1586/17474086.2.1.17 · Cited by 21

GROWTH FACTORS AND HEMATOPOIETIC STEM CELLS

Veiby, O. P., Mikhail, A. A., & Snodgrass, H. R. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70487-1 · Cited by 21

Treatment of Non-Obese Diabetic (NOD)/Severe-Combined Immunodeficient Mice (SCID) With flt3 Ligand and Interleukin-7 Impairs the B-Lineage Commitment of Repopulating Cells After Transplantation of Human Hematopoietic Cells

Kapp, U., Bhatia, M., Bonnet, D. A., Murdoch, B., & Dick, J. E. (1998) · Blood · doi:10.1182/blood.v92.6.2024 · Cited by 21

Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core

Xu, J., Ong, E. H., Hill, J., Chen, A., & Chai, C. L. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.10.006 · Cited by 20

Human FLT3 ligand acts on myeloid as well as multipotential progenitors derived from purified CD34+ blood progenitors expressing different levels of c‐kit protein

Sonoda, Y., Kimura, T., Sakabe, H., Tanimukai, S., Ohmizono, Y., Nakagawa, S., Yokota, S., Lyman, S. D., & Abe, T. (1997) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1997.tb01664.x · Cited by 20

Effect of FLT3 Inhibition on Normal Hematopoietic Progenitor Cells

Weisel, K. C., YILDIRIM, S., Schweikle, E., Kanz, L., & Möhle, R. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1392.020 · Cited by 20

FLT-3 LIGAND INCREASES MICROCHIMERISM BUT CAN PREVENT THE THERAPEUTIC EFFECT OF DONOR BONE MARROW IN TRANSIENTLY IMMUNOSUPPRESSED CARDIAC ALLOGRAFT RECIPIENTS

Thomson, A. W., Antonysamy, M. A., Steptoe, R. J., Khanna, A., Rudert, W. A., & Subbotin, V. M. (1998) · Transplantation · doi:10.1097/00007890-199806270-00151 · Cited by 20

SZF1

Liu, C., Levenstein, M. E., Chen, J., Tsifrina, E., Yonescu, R., Griffin, C. A., Civin, C. I., & Small, D. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(98)00035-6 · Cited by 19

Ex vivo expansion of haemopoietic progenitor cells

Alcorn, M. J., & Holyoake, T. L. (1996) · Blood Reviews · doi:10.1016/s0268-960x(96)90023-5 · Cited by 19

Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents

Stein, E. M., & Yen, K. E. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122051 · Cited by 18

A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

Sellmer, A., Pilsl, B., Beyer, M., Pongratz, H., Wirth, L., Elz, S., Dove, S., Henninger, S. J., Spiekermann, K., Polzer, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112232 · Cited by 18

Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death

Molina, M. S., Hoffman, E. A., Stokes, J., Kummet, N., Smith, K. A., Baker, F. L., Zúñiga, T. M., Simpson, R. J., & Katsanis, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699128 · Cited by 18

FLT3/ITD Associated with an Immature Immunophenotype in PML-RARα Leukemia

Takenokuchi, M., Kawano, S., Nakamachi, Y., Sakota, Y., Syampurnawati, M., Saigo, K., Tatsumi, E., & Kumagai, S. (2012) · Hematology Reports · doi:10.4081/4380 · Cited by 18

Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease

Baldwin, B. R., Li, L., Tse, K.-F., Small, S. H., Collector, M. I., Whartenby, K. A., Sharkis, S. J., Racke, F. K., Huso, D. L., & Small, D. (2007) · Leukemia · doi:10.1038/sj.leu.2404532 · Cited by 18

Flt-3 Ligand Increases Microchimerism But Can Prevent the Therapeutic Effect of Donor Bone Marrow in Transiently Immunosuppressed Cardiac Allograft Recipients

Antonysamy, M. A., Steptoe, R. J., Khanna, A., Rudert, W. A., Subbotin, V. M., & Thomson, A. W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.8.4106 · Cited by 18

New agents for acute myeloid leukemia: is it time for targeted therapies?

Ferrara, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.646082 · Cited by 17

Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells

Weisel, K. C., Yildirim, S., Schweikle, E., Kanz, L., & Möhle, R. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0605-6 · Cited by 17

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

Patel, A. B., Pomicter, A. D., Yan, D., Eiring, A. M., Antelope, O., Schumacher, J. A., Kelley, T. W., Tantravahi, S. K., Kovacsovics, T. J., Shami, P. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0858-1 · Cited by 17

4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors

Gaul, M. D., Xu, G., Kirkpatrick, J., Ott, H. M., & Baumann, C. A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.046 · Cited by 17

Reducing chemotherapy-associated toxicity in elderly cancer patients

Zagonel, V., Fratino, L., Sacco, C. S. P., Babare, R., Spazzapan, S., Gattei, V., Improta, S., & Pinto, A. (1996) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(96)90003-1 · Cited by 17

Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia

Obermann, E. C., Arber, C., Jotterand, M., Tichelli, A., Hirschmann, P., & Tzankov, A. (2010) · Annals of Hematology · doi:10.1007/s00277-009-0890-8 · Cited by 16

Ex Vivo Expansion of Cord Blood Progenitors

Piacibello, W., Sanavio, F., Severino, A., Garetto, L., Danè, A., Gammaitoni, L., & Aglietta, M. (1998) · Vox Sanguinis · doi:10.1111/j.1423-0410.1998.tb05456.x · Cited by 16

SDF-1 enhances the expansion and maintenance of highly purified human hematopoietic progenitors

Rosu‐Myles, M., & Bhatia, M. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200233 · Cited by 16

Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy

Bojko, P., Pawloski, D., Stellberg, W., der, J. S. X. F., & Seeber, S. (2002) · Annals of Hematology · doi:10.1007/s00277-002-0535-7 · Cited by 16

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias

Banerji, L., & Sattler, M. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.3.221 · Cited by 16

FLT-3 Ligand and Marrow Stroma-Derived Factors Promote CD3γ, CD3δ, CD3ζ, and RAG-2 Gene Expression in Primary Human CD34+LIN−DR− Marrow Progenitors

Gaffney, P. M., Lund, J., & Miller, J. S. (1998) · Blood · doi:10.1182/blood.v91.5.1662 · Cited by 16

Novel Therapeutics in Acute Myeloid Leukemia

Sweet, K. L., & Lancet, J. E. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0199-0 · Cited by 15

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia

Karnan, S., Hanamura, I., Ota, A., Takasugi, S., Nakamura, A., Takahashi, M., Uchino, K., Murakami, S., Wahiduzzaman, M., Vu, L. Q., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00446-8 · Cited by 15

Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells

Oveland, E., Gjertsen, B. T., Wergeland, L., Selheim, F., Fladmark, K. E., & Hovland, R. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.029 · Cited by 15

Cytokines at the research-clinical interface: potential applications

Holyoake, T. L. (1996) · Blood Reviews · doi:10.1016/s0268-960x(96)90026-0 · Cited by 15

Identification and Characterization of a Functional Murine FLT3 Isoform Produced by Exon Skipping

Lavagna, C., Marchetto, S., Birnbaum, D., & Rosnet, O. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.3165 · Cited by 14

Novel potential ALL low-risk markers revealed by gene expression profiling with new high-throughput SSH–CCS–PCR

Qiu, J., Gunaratne, P. H., Peterson, L. E., Khurana, D., Walsham, N., Loulseged, H., Karni, R. J., Roussel, E., Gibbs, R. A., Margolin, J., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403073 · Cited by 14

Gastrointestinal Stromal Tumors: A Paradigm for Molecularly Targeted Therapy

von Mehren, M. (2003) · Cancer Investigation · doi:10.1081/cnv-120022374 · Cited by 14

IL-6 precludes the differentiation induced by IL-3 on expansion of CD34+ cells from cord blood.

Encabo, A., Mateu, E., Carbonell‐Uberos, F., & Miñana, M. D. (2003) · PubMed · Cited by 14

Stem Cell Factor as a Survival and Growth Factor in Human Normal and Malignant Hematopoiesis

Hassan, H. T., & Zander, A. R. (1996) · Springer eBooks · doi:10.1007/978-1-4613-0391-6_66 · Cited by 13

Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner

Mitina, O., Warmuth, M., Krause, G., Hallek, M. J., & Obermeier, A. (2007) · Annals of Hematology · doi:10.1007/s00277-007-0344-0 · Cited by 13

Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C2 and C6 positions

Oh, C., Kim, H., Kang, J. S., Yun, J., Sim, J. J., Kim, H.-M., & Han, G. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.034 · Cited by 13

Purification and Expansion of Human Hematopoietic Stem/Progenitor Cells

Civin, C. I., & SMALL, D. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb31046.x · Cited by 13

Haematopoietic action of flt3 ligand on cord blood‐derived CD34‐positive cells expressing different levels of flt3 or c‐kit tyrosine kinase receptor: comparison with stem cell factor

Sakabe, H., Kimura, T., Zeng, Z.-Z., Minamiguchi, H., Tsuda, S., Yokota, S., Hodohara, K., Abe, T., Lyman, S. D., & Sonoda, Y. (1998) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1998.tb01043.x · Cited by 13

Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits

Pless, M., Wodnar‐Filipowicz, A., John, L., Baldomero, H., Lyman, S. D., Nissen, C., & Gratwohl, A. A. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(98)00022-8 · Cited by 13

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

Bertoli, S., Dumas, P., Bérard, E., Largeaud, L., Bidet, A., Delabesse, É., Tavitian, S., Gadaud, N., Leguay, T., Leroy, H., et al. (2020) · Cancers · doi:10.3390/cancers12040773 · Cited by 12

Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance?

McKenna, H. J. (1999) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050576 · Cited by 12

FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells

Araújo, J. L., Wagenblast, E., Voisin, V., McLeod, J. L., Gan, O. I., Bansal, S., Jin, L., Mitchell, A., Gratton, B., Cutting, S. K., et al. (2025) · Blood · doi:10.1182/blood.2024025886 · Cited by 11

Differences in gene expression between individuals with multiple primary and single primary malignancies

Stathopoulos (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000272 · Cited by 11

FLT3 inhibitors in acute myeloid leukemia

El‐Shami, K., Stone, R. M., & Smith, B. D. (2008) · Expert Review of Hematology · doi:10.1586/17474086.1.2.153 · Cited by 11

Effect of imatinib on haematopoietic recovery following idarubicin exposure

Ruchatz, H., Puttini, M., Cleris, L., Pilotti, S., Gambacorti-Passerini, C. B., & Formelli, F. (2003) · Leukemia · doi:10.1038/sj.leu.2402800 · Cited by 11

Will newer tyrosine kinase inhibitors have an impact in AML?

Levis, M. J. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.09.008 · Cited by 10

Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress

Zhao, J., Wu, M., Li, Z., Su, S., Wen, Y., Zhang, L., & Li, Y. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04020-7 · Cited by 10

Cutting Edge Molecular Therapy for Acute Myeloid Leukemia

Miyamoto, K., & Minami, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145114 · Cited by 11

Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines

Oveland, E., Wergeland, L., Hovland, R., Lorens, J. B., Gjertsen, B. T., & Fladmark, K. E. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-012-9216-z · Cited by 10

The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with flt3 ligand, interleukin‐3 or granulocyte‐macrophage colony stimulating factor

Hjertson, M., Sundström, C., Nilsson, K., & Nilsson, G. P. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01198.x · Cited by 10

Development of Functional Human Immune System With the Transplantations of Human Fetal Liver/Thymus Tissues and Expanded Hematopoietic Stem Cells in RAG2−/−γc−/− MICE

Joo, S.-Y., Choi, B.-K., Kang, M.-S., Jung, D. Y., Park, K. S., Park, J. B., Choi, G., Joh, J., Kwon, C. H. D., Jung, G. O., et al. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.02.074 · Cited by 10

Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer

Dong, J. P., Bohinski, R. J., Li, Y., Waes, C. V., Hendler, F. J., Gleich, L. L., & Stambrook, P. J. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700534 · Cited by 10

Administration of Flk2/Flt3 ligand induces expansion of human high-proliferative potential colony-forming cells in the SCID-hu mouse

Namikawa, R., Muench, M. O., Firpo, M. T., Humeau, L. M. P. F., Xu, Y., Menon, S., & Roncarolo, M. G. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00034-x · Cited by 10

Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

Tecik, M., & Adan, A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01202-7 · Cited by 9

Significant Reduction of Laparotomy-Associated Lung Metastases and Subcutaneous Tumors After Perioperative Immunomodulation with Flt3 Ligand in Mice

Carter, J. J., Feingold, D. L., Wildbrett, P., Oh, A., Kirman, I., Asi, Z., Stapleton, G., Huang, E. H., Fine, R. L., & Whelan, R. L. (2005) · Surgical Innovation · doi:10.1177/155335060501200406 · Cited by 9

Perioperative Immunomodulation With Flt3 Kinase Ligand or a Whole Tumor Cell Vaccine Is Associated With a Reduction in Lung Metastasis Formation After Laparotomy in Mice

Carter, J. J., Feingold, D. L., Oh, A., Kirman, I., Wildbrett, P., Stapleton, G., Asi, Z., Fowler, R., Bhagat, G., Huang, E. H., et al. (2006) · Surgical Innovation · doi:10.1177/155335060601300107 · Cited by 9

Abnormalities of p51, p53, FLT3 and N-ras Genes and Their Prognostic Value in Relapsed Acute Myeloid Leukemia

Nakamura, H., Inokuchi, K., Yamaguchi, H., & Dan, K. (2004) · Journal of Nippon Medical School · doi:10.1272/jnms.71.270 · Cited by 9

Establishment of Mouse Embryonic Fibroblast Cell Lines That Promote Ex Vivo Expansion of Human Cord Blood CD34 + Hematopoietic Progenitors

Qiu, H., Fujimori, Y., Kai, S., Fujibayashi, Y., Nishioka, K., & Hara, H. (2003) · Stem Cells and Development · doi:10.1089/152581603321210127 · Cited by 9

Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children

Clark, J., Berman, J. N., & Look, A. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00011-x · Cited by 9

FLT3/FLK‐2 (STK‐1) Ligand Does Not Stimulate Human Megakaryopoiesis In Vitro

Ratajczak, M. Z., Ratajczak, J., Ford, J. C., Kregenow, R., Marlicz, W. M., & Gewirtz, A. M. (1996) · Stem Cells · doi:10.1002/stem.140146 · Cited by 22

Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells

Zeigler, F., Bennett, B., Jordan, C. T., Spencer, S., Baumhueter, S., Carroll, K., Hooley, J., Bauer, K., & Matthews, W. (1994) · Blood · doi:10.1182/blood.v84.8.2422.2422 · Cited by 137

Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells

Iwama, A., Okano, K., Sudo, T., Matsuda, Y., & Suda, T. (1994) · Blood · doi:10.1182/blood.v83.11.3160.3160 · Cited by 143

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

Matthews, W., Jordan, C. T., Wiegand, G. W., Pardoll, D., & Lemischka, I. R. (1991) · Cell · doi:10.1016/0092-8674(91)90010-v · Cited by 593

A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.

Matthews, W., Jordan, C. T., Gavin, M. A., Jenkins, N. A., Copeland, N. G., & Lemischka, I. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9026 · Cited by 502